ANSTO National Medical Facility to Triple Production of Radiopharmaceuticals
ANM project at ANSTO will benefit the Australian health industry and position Australia as a global leader in the high-end manufacturing of nuclear medicine. Through this project, Australia will be able to triple production of molybdenum-99 (Mo-99). ANSTO currently delivers the equivalent of 10,000 patient doses of Mo-99 across Australia each week. The ANM Project includes a nuclear medicine manufacturing plant and a waste treatment plant to treat by-products for permanent, safe storage at a national waste repository. The project is worth $168.8 million and subject to required approvals the plant will be operational from 2016.
Click here to read full article: www.ansto.gov.au